About Graver Research
Graver Research publishes independent research on publicly traded healthcare services companies.
The analysis connects company fundamentals and market expectations with the broader industry and financial context, including utilization, reimbursement, policy and regulation, competitive dynamics, market structure, valuation, and capital allocation. Each piece explains why a development matters, how it may affect companies and subsectors, and what to watch next.
Research coverage
Current coverage is anchored in managed care, hospitals and facility-based care, healthcare distribution, and CRO / outsourcing. Adjacent providers, diagnostics, healthcare technology, and other healthcare services businesses are included when relevant.
Research is published in several formats:
Company research
Earnings previews and post-event analysis
Policy, reimbursement, and regulatory read-throughs
Company and sector KPI, data, and valuation analysis
Coverage maps and debate trackers
Primers and explainers on complex healthcare services topics
Who it is for
Graver Research is intended for investors and healthcare professionals who need to understand how company performance, industry developments, and market expectations interact.
The audience includes professional investors; individual investors who follow healthcare closely; healthcare executives and operators; corporate strategy, finance, and investor-relations teams; consultants and advisors; and others whose work requires a close understanding of the sector.
The core research assumes some familiarity with financial statements and healthcare terminology. Primers and explainers provide additional context when useful.
Start here
New readers may want to begin with:
Healthcare Services Coverage Map: The Initial Universe and Key Debates — An overview of the initial coverage universe and the company and subsector debates Graver Research will track.
UNH 2Q26 Preview: The First Real Test of the Rebuild — A company preview centered on claims completion, reserve quality, repricing, and the earnings-recovery debate.
HCA 2Q26 Pre-Announcement: Traffic Rebounds, but Mix Pressure Drives an EBITDA Guide Cut — Event analysis separating patient traffic from payer mix, surgical mix, and earnings quality.
ELV 2Q26: The Beat Was Real, but Medicaid Still Has to Prove the Turn — A post-earnings assessment of normalized results and the continuing Medicaid margin debate.
About Tyler Graver
Graver Research is written by Tyler Graver, an independent healthcare services analyst with more than a decade of equity research and finance experience.
Before launching Graver Research, Tyler covered healthcare services in both sell-side research and buy-side investing, including at a bulge-bracket investment bank and a large healthcare-dedicated investment firm. His experience spans public equity research, long/short and long-only investing, special situations, and private and venture-stage healthcare investing.
His work has focused on public healthcare services companies, reimbursement systems, policy developments, market structure, and company-specific investment debates.
Subscribe
Subscribe for free to receive new research by email as it is published.
Contact
Questions, feedback, and relevant source material are welcome at:
Disclaimer
Graver Research is published by Graver Analysis LLC.
The content published by Graver Research is for informational and educational purposes only. It does not constitute investment advice, legal advice, tax advice, accounting advice, or any recommendation or offer to buy, sell, or hold any security or financial instrument.
Nothing published by Graver Research should be understood as personalized advice or as a recommendation tailored to any individual reader’s financial situation, investment objectives, risk tolerance, or time horizon. Readers should conduct their own research and consult appropriate professional advisers before making investment or business decisions.
Graver Research may discuss public companies, securities, industries, policy developments, and market events. The author, Graver Analysis LLC, or related parties may hold positions in securities or companies discussed and may buy, sell, or otherwise change those positions at any time without notice. Where relevant, Graver Research will seek to disclose material conflicts or positions.
All views expressed are those of the author unless otherwise stated. While Graver Research seeks to use sources believed to be reliable, no representation is made as to the accuracy, completeness, or timeliness of any information. Graver Research has no obligation to update any information after publication.
All content is copyright © 2026 Graver Analysis LLC. All rights reserved.
